Swedish Orphan Biovitrum (Buy, TP: SEK265.00) - Strong Q4 expected
SOBI is set to report Q4 earnings at 08:00 CET on 8 February. We expect a strong quarter and that the company will beat its 2022 guidance for earnings and margins. We expect operations within haemophilia to remain stable with growth coming from new products. With a strong RSV season, sales of Synagis should be solid and thus also margins in Q4. We believe 2023 guidance will be in line with consensus for growth and margins. We reiterate our BUY and SEK265 target price.Swedish Orphan Biovitrum AB is a healthcare company focused on rare diseases. Co. develops, manufactures and commercializes treatments with a particular focus on four therapeutic areas: Inflammation, Genetics & Metabolism, Haemophilia and Neonatology. Co. also markets a portfolio of rare disease products for partner companies. Co.'s pipeline programmes include research and development focused on recombinant protein drugs in late preclinical and clinical phase for indications.
DNB Markets is the investment banking arm of DNB Bank ASA and is focused primarily on the Nordic region, as well as internationally on niches such as global shipping, energy and related services, and seafood. DNB Markets offers services in FICC, Equities and Investment Banking advisory from offices in Oslo, Stockholm, London, Singapore and New York. Equity research coverage is offered on c250 Nordic companies. DNB was ranked no.2 in Extel Nordic Research 2017. The DNB Markets’ Credit and FICC Macro & FX Research teams are repeatedly highly rated by Prospera Nordic Institutional Investor Surveys.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.